103 related articles for article (PubMed ID: 25605437)
1. PET-Florbetapir findings in primary cerebral amyloidoma.
Villarejo-Galende A; Sarandeses P; Penas-Prado M; Hernández-Laín A; Ramos A; Hernández-Martínez AC; Carro E; Ricoy JR; Hernández-Gallego J
J Neurol; 2015; 262(4):1052-4. PubMed ID: 25605437
[No Abstract] [Full Text] [Related]
2. 18F-Florbetapir PET in Primary Cerebral Amyloidoma.
Soffers F; Ceyssens S; Buffet W; de Surgeloose D; Crols R
Clin Nucl Med; 2020 Oct; 45(10):838-839. PubMed ID: 32796236
[TBL] [Abstract][Full Text] [Related]
3. Imaging cardiac amyloidosis: a pilot study using ¹⁸F-florbetapir positron emission tomography.
Dorbala S; Vangala D; Semer J; Strader C; Bruyere JR; Di Carli MF; Moore SC; Falk RH
Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1652-62. PubMed ID: 24841414
[TBL] [Abstract][Full Text] [Related]
4. 18F-Florbetapir and 18F-FDG PET/CT in Systemic Immunoglobulin Light Chain Amyloidosis Involving the Peripheral Nerves.
Broski SM; Spinner RJ; Howe BM; Dispenzieri A; Johnson GB
Clin Nucl Med; 2016 Feb; 41(2):e115-7. PubMed ID: 26284768
[TBL] [Abstract][Full Text] [Related]
5. Detection of ALECT2 amyloidosis by positron emission tomography-computed tomography imaging with florbetapir.
Leung N; Ramirez-Alvarado M; Nasr SH; Kemp BJ; Johnson GB
Br J Haematol; 2017 Apr; 177(1):12. PubMed ID: 28107549
[No Abstract] [Full Text] [Related]
6. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.
Joshi AD; Pontecorvo MJ; Lu M; Skovronsky DM; Mintun MA; Devous MD
J Nucl Med; 2015 Nov; 56(11):1736-41. PubMed ID: 26338898
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Amyloidosis Detected Using
García-González P; Cozar-Santiago MDP; Maceira AM
Rev Esp Cardiol (Engl Ed); 2016 Dec; 69(12):1215. PubMed ID: 27178118
[No Abstract] [Full Text] [Related]
8. Abnormal pulmonary
Pittman S; Sethi P; Flavell RR; De Marco T; Hernandez Pampaloni M
J Nucl Cardiol; 2018 Oct; 25(5):1865-1868. PubMed ID: 29101671
[No Abstract] [Full Text] [Related]
9. Utility of the
Mestre-Torres J; Lorenzo-Bosquet C; Cuberas-Borrós G; Gironella M; Solans-Laque R; Fernández-Codina A; Bujan-Rivas S; Castell-Conesa J; Martínez-Valle F
Amyloid; 2018 Jun; 25(2):109-114. PubMed ID: 29706127
[TBL] [Abstract][Full Text] [Related]
10. Molecular imaging of misfolded protein pathology for early clues to involvement of the heart.
Merlini G; Narula J; Arbustini E
Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1649-51. PubMed ID: 24990402
[No Abstract] [Full Text] [Related]
11. A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement.
Manwani R; Page J; Lane T; Burniston M; Skillen A; Lachmann HJ; Gillmore JD; Fontana M; Whelan C; Hawkins PN; Wagner T; Wechalekar AD
Amyloid; 2018 Dec; 25(4):247-252. PubMed ID: 30661419
[No Abstract] [Full Text] [Related]
12. Extracardiac
Wagner T; Page J; Burniston M; Skillen A; Ross JC; Manwani R; McCool D; Hawkins PN; Wechalekar AD
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1129-1138. PubMed ID: 29651545
[TBL] [Abstract][Full Text] [Related]
13. Novel imaging techniques using
Shouman K; Broski SM; Muchtar E; Pendleton CA; Johnson GB; Tracy J; Engelstad JK; Spinner RJ; Dyck PJB
Muscle Nerve; 2021 Jan; 63(1):104-108. PubMed ID: 33094511
[TBL] [Abstract][Full Text] [Related]
14. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
[TBL] [Abstract][Full Text] [Related]
15. Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.
Lister-James J; Pontecorvo MJ; Clark C; Joshi AD; Mintun MA; Zhang W; Lim N; Zhuang Z; Golding G; Choi SR; Benedum TE; Kennedy P; Hefti F; Carpenter AP; Kung HF; Skovronsky DM
Semin Nucl Med; 2011 Jul; 41(4):300-4. PubMed ID: 21624563
[TBL] [Abstract][Full Text] [Related]
16. Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
Namiki C; Takita Y; Iwata A; Momose T; Senda M; Okubo Y; Joshi AD; Lu M; Agbulos A; Breault C; Pontecorvo MJ
Ann Nucl Med; 2015 Aug; 29(7):570-81. PubMed ID: 25943346
[TBL] [Abstract][Full Text] [Related]
17. Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.
Cortes-Blanco A; Prieto-Yerro C; Martinez-Lazaro R; Zamora J; Jiménez-Huete A; Haberkamp M; Pohly J; Enzmann H; Zinserling J; Strassmann V; Broich K
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S395-9. PubMed ID: 24418060
[TBL] [Abstract][Full Text] [Related]
18. Comment on Hsiao et al.: Correlation of early-phase ¹⁸F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies.
Ballinger JR
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1512; author reply 1513. PubMed ID: 22644710
[No Abstract] [Full Text] [Related]
19. Quantification of 18F-florbetapir PET: comparison of two analysis methods.
Hutton C; Declerck J; Mintun MA; Pontecorvo MJ; Devous MD; Joshi AD;
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):725-32. PubMed ID: 25652817
[TBL] [Abstract][Full Text] [Related]
20. Technical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir.
Trembath L; Newell M; Devous MD
J Nucl Med Technol; 2015 Sep; 43(3):175-84. PubMed ID: 26271806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
